Beijing Tiantan Biological Products Corp Ltd (600161)

Currency in CNY
11.94
-0.08(-0.67%)
Closed·
600161 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
11.8912.13
52 wk Range
11.1218.32
Key Statistics
Bid/Ask
11.94 / 11.95
Prev. Close
11.94
Open
12.03
Day's Range
11.89-12.13
52 wk Range
11.12-18.32
Volume
10.09M
Average Volume (3m)
12.52M
1-Year Change
-34.6112%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
600161 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
14.47
Upside
+21.16%
Members' Sentiments
Bearish
Bullish
ProTips
Prominent player in the Biotechnology industry

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

3 Buy
1 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 14.47
(+21.16% Upside)

Earnings

Latest Release
Oct 30, 2026
EPS / Forecast
0.07 / 0.11
Revenue / Forecast
1.26B / 1.02B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.36
Dividend Yield
1.25%
Industry Median 1.84%
Annualised payout
0.15
Paid unevenly
5-Years Growth
+16.67%
Growth Streak

600161 Income Statement

Compare 600161 to Peers and Sector

Metrics to compare
600161
Peers
Sector
Relationship
P/E Ratio
33.7x22.5x−0.2x
PEG Ratio
−0.740.030.00
Price/Book
2.0x1.9x2.6x
Price / LTM Sales
4.3x5.1x2.7x
Upside (Analyst Target)
21.2%40.0%68.5%
Fair Value Upside
Unlock19.5%11.5%Unlock

Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and marketing of blood products in China and internationally. Its products include human serum albumin; intravenous human immunoglobulin; rabies immunoglobulin; tetanus immunoglobulin; hepatitis B immunoglobulin; freeze-dried intravenous hepatitis B human immunoglobulin; histamine human immunoglobulin; human prothrombin complex concentrate; lyophilized intravenous hepatitis B immunoglobulin; human coagulation factors VIII; human fibrinogen; recombinant human coagulation factor VIII for injection; and other blood products. The company was founded in 1966 and is headquartered in Beijing, China.

Employees
5205
Market
China

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
132.08M6.68%1.60B
Other Institutional Investors
1.03B52.17%12.51B
Public Companies & Retail Investors
813.78M41.15%9.87B
Total
1.98B100.00%23.99B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
China National Pharmaceutical Group Corporation46.59%921,302,85411,175,404
Chengdu Bio-product Research Institute3.53%69,817,435846,885

People Also Watch

18.36
600233
+0.05%
7.58
600661
-1.43%
32.54
601601
-0.31%

FAQ

What Is the BTBP (600161) Stock Price Today?

The BTBP stock price today is 11.94 CNY.

What Stock Exchange Does BTBP Trade On?

BTBP is listed and trades on the Shanghai Stock Exchange.

What Is the Stock Symbol for BTBP?

The stock symbol for BTBP is "600161."

What Is the BTBP Market Cap?

As of today, BTBP market cap is 23.61B CNY.

What Is BTBP's Earnings Per Share (TTM)?

The BTBP EPS (TTM) is 0.36.

When Is the Next BTBP Earnings Date?

BTBP will release its next earnings report on Apr 27, 2027.

From a Technical Analysis Perspective, Is 600161 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has BTBP Stock Split?

BTBP has split 9 times.

How Many Employees Does BTBP Have?

BTBP has 5205 employees.

What is the current trading status of BTBP (600161)?

As of Nov 18, 2026, BTBP (600161) is trading at a price of 11.94 CNY, with a previous close of 11.94 CNY. The stock has fluctuated within a day range of 11.89 CNY to 12.13 CNY, while its 52-week range spans from 11.12 CNY to 18.32 CNY.

What Is BTBP (600161) Price Target According to Analysts?

The average 12-month price target for BTBP is 14.47 CNY, with a high estimate of 15 CNY and a low estimate of 13.4 CNY. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +21.16% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.